Open an account

Avalyn Pharma

AVLN · NASDAQ

$24.63+$1.30 (+5.57%)TodayMarket closed ·
Prev close $23.33

About AVLN

Avalyn Pharma, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Boston, Massachusetts and currently employs 51 full-time employees. The company went IPO on 2026-04-30. The firm's pipeline is focused on treating pulmonary fibrosis. The company has three approved oral antifibrotic therapies for pulmonary fibrosis: pirfenidone; nintedanib, and nerandomilast. Its clinically advanced candidates, AP01 and AP02, are inhaled formulations of pirfenidone and nintedanib for the treatment of progressive pulmonary fibrosis and idiopathic pulmonary fibrosis, respectively. The company has completed ATLAS, a Phase 1b clinical trial of AP01 in patients with IPF. AP02 is being evaluated in AURA, a global Phase II clinical trial for the treatment of IPF. The company is also advancing AP03 into a Phase I clinical trial. AP03 is a fixed-dose combination of inhaled pirfenidone, and nintedanib designed to deliver dual antifibrotic mechanisms with the potential for additive or synergistic benefit.

Employees
51
Headquarters
Boston, Massachusetts
Listed
Apr 30, 2026
Sector
Health Care
Industry
Pharmaceuticals
Website
avalynpharma.com

AVLN key statistics

Market cap
1.03B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
315.93K
Volume
217.52K
Open price
$23.33
High today
$24.75
Low today
$22.24
52 Week high
$40.17
52 Week low
$22.68

Avalyn Pharma (AVLN) at a glance

Avalyn Pharma (AVLN) last traded at $24.63, with a market cap of 1.03B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $22.24 and $24.75. The current price is 10.7% above the day's low and 0.5% below its high.

Volume so far is 217.52K shares, below the average of 315.93K shares a day.

Over the past year Avalyn Pharma has ranged from $22.68 to $40.17, and now sits 11% of the way up that range.

The average analyst price target is $63.49, 157.8% above the current price, from 4 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 4 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 6 analystsAvg $63.49
Low
$52.52
Now
$24.63
High
$84.00

AVLN news

  • Press releaseGlobe Newswire

    Avalyn to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

  • Press releaseGlobe Newswire

    Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights

  • Press releaseGlobe Newswire

    Avalyn to Participate in the Jefferies Global Healthcare Conference

  • Press releaseBusiness Wire

    Two River and Vida Ventures Extend Track Record of Company Creation and Value Realization Following the Candid Therapeutics' Acquisition by UCB

Similar companies

Companies in the same industry as Avalyn Pharma

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.